Skylit Medical
We're developing a connected device to bring access to clear skin to over 40 million people in the US and 500 million worldwide who have psoriasis and eczema..
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
$400k | Series A | ||
| Total Funding | 000k | ||
Related Content
Founded in 2013 by Martyn Gross and Remo M Qajar, Skylit Medical operated from San Diego, United States, with a focus on developing phototherapy-based devices. The company, which later changed its name to Clarify Medical in 2016, aimed to provide at-home treatments for chronic skin conditions like psoriasis, eczema, and vitiligo. The inspiration for the company came from founder Martyn Gross's own frustrating experience as a psoriasis patient, finding clinical phototherapy effective but highly inconvenient and costly. This personal journey led to the creation of a connected, handheld device that patients could use in the comfort of their homes.
Skylit Medical developed a handheld device that utilized LED technology to deliver prescription phototherapy. A key feature was its connectivity; the device could be remotely programmed by physicians and would transmit usage data back to dermatologists via a mobile app, allowing for remote monitoring and ensuring treatment compliance. The system was designed for localized treatment of skin conditions on all skin types (I-VI). The business model centered on providing a more accessible and private alternative to traditional in-clinic phototherapy sessions. The company successfully raised a total of $1.85 million in funding over four rounds, with investors including Serra Ventures and FOUNDER.org. Its final funding round was a Series A for $400,000 on April 21, 2016.
The company received 510(k) premarket notification from the FDA for its phototherapy system in May 2017 under the name Clarify Medical. The system, which included the handheld UV light device and a smartphone application, was intended for treating conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), and seborrheic dermatitis. In September 2016, as the company prepared for FDA submission and market introduction, Martyn Gross transitioned from CEO to VP of Innovation, and James M. Sweeney was appointed as the new CEO. Following these developments, the company was eventually reported as deadpooled. Keywords: phototherapy, dermatology, psoriasis treatment, eczema treatment, vitiligo treatment, home medical device, connected health, remote patient monitoring, LED therapy, UVB phototherapy, Clarify Medical, Martyn Gross, skin conditions, medical device, telehealth, prescription phototherapy, at-home healthcare, chronic skin disease, dermatological device, skincare technology